Raynauds Disease – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Raynauds Disease – Pipeline Review, H1 2017’, provides an overview of the Raynauds Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Raynauds Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Raynauds Disease and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Raynauds Disease

The report reviews pipeline therapeutics for Raynauds Disease by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Raynauds Disease therapeutics and enlists all their major and minor projects

The report assesses Raynauds Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Raynauds Disease

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Raynauds Disease

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Raynauds Disease pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Allergan Plc

Apricus Biosciences Inc

Covis Pharmaceuticals Inc

Human Stem Cells Institute

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Raynauds Disease - Overview

Raynauds Disease - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Raynauds Disease - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Raynauds Disease - Companies Involved in Therapeutics Development

Allergan Plc

Apricus Biosciences Inc

Covis Pharmaceuticals Inc

Human Stem Cells Institute

Raynauds Disease - Drug Profiles

alprostadil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Block TRPM8 for Raynauds Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ELS-140 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neovasculgen - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nitroglycerin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Raynauds Disease - Dormant Projects

Raynauds Disease - Discontinued Products

Raynauds Disease - Product Development Milestones

Featured News & Press Releases

Mar 08, 2016: Apricus Biosciences to Present at the 28th Annual ROTH Conference

Feb 02, 2016: Apricus Biosciences to Present at the 18th Annual BIO CEO & Investor Conference, Provide Update on Vitaros

Aug 05, 2015: Apricus Biosciences to Provide Update On The European Launch of Vitaros at the Canaccord Genuity 35th Annual Growth Conference

Apr 28, 2015: Apricus Biosciences to Present at Two Investor Conferences in May

Jan 27, 2015: Apricus Biosciences Announces Issuance of U.S. Patent for RayVa

Dec 04, 2014: Apricus Biosciences Announces First Patient Enrolled In Phase 2a Clinical Trial For RayVa In Patients With Raynaud's Phenomenon

Oct 13, 2014: Apricus Biosciences Announces Notice of Allowance of U.S. Patent Application for RayVa

Oct 01, 2014: Apricus Biosciences to Present at the 13th Annual BIO Investor Forum

May 12, 2014: Apricus Biosciences Receives FDA Clearance to Begin Clinical Trial of RayVa for Secondary Raynaud's Phenomenon

Dec 13, 2012: MediQuest Therapeutics To Conduct Meetings At J.P. Morgan Conference Regarding Phase III Topical Formulation Vascana

May 31, 2011: Apricus Bio Receives Israeli Patent For RayVa For Raynaud's Phenomenon

Apr 13, 2011: Apricus Bio Files For Orphan Drug Designation For RayVa

Sep 22, 2010: FDA Guides Apricus Bio On RayVa's Approvability For Raynaud's Syndrome Secondary To Scleroderma

Jan 10, 2006: MediQuest Therapeutics Receives Special Protocol Assessment From The U.S. FDA

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Raynauds Disease, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Raynauds Disease – Pipeline by Allergan Plc, H1 2017

Raynauds Disease – Pipeline by Apricus Biosciences Inc, H1 2017

Raynauds Disease – Pipeline by Covis Pharmaceuticals Inc, H1 2017

Raynauds Disease – Pipeline by Human Stem Cells Institute, H1 2017

Raynauds Disease – Dormant Projects, H1 2017

Raynauds Disease – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Raynauds Disease, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports